We start with the evidence. We don't stop there.
Policy Shaping & Life Science Consulting for life science. We built our name on evidence rigorous enough to win an HTA argument, and we turn that rigour into strategy, decisions and the policy environment around them.
What we do
Two jobs: make the evidence undeniable, then make it count.
Most clients have plenty of data. What they lack is a clear line from it to a decision, and the strategy to shape what the decision-maker does next.
So we work as two halves of one job. Policy shaping works on the environment access decisions live in. Life science consulting brings the disciplines that turn evidence into those decisions. The rigour that wins an HTA argument runs through both.
Policy shaping
Access is shaped, not just won.
Access decisions are made by people, inside systems and frameworks that are still being written. Much of this work is relationships and conversations: bringing the right people together, early and often, to shape the environment a product launches into.
Shaping the access environment
Work with HTA bodies, payers and policymakers to help shape the frameworks and criteria a product will be judged against, rather than only responding once they are set.
Local engagement plans
Country-by-country plans that map who matters in each Nordic market, what they care about and when to engage, so the groundwork is done well before a decision is on the table.
Advisory boards and roundtables
Convene clinicians, payers and experts in advisory boards and roundtable meetings to test the value story, surface concerns early and build shared understanding.
Stakeholder engagement
Build relationships and support across payers, clinicians, patient organisations, scientific experts and policymakers.
Narrative and communication
Shape complex evidence into a clear value story, with the messages, publications and materials that carry it to decision-makers.
Evidence strategy for HTA
When the submission itself is in scope, plan for the questions a modern assessment will ask, from comparators to local transferability.
Life science consulting
Every discipline your problem needs, in one team.
Health economics, real-world evidence, biostatistics, market access, pricing and scientific communication, under one roof. We bring the right mix to the question in front of you, and connect it to the decision it has to support.
One multidisciplinary team
Academic rigour balanced with practical, ex-payer experience, so the work is both defensible and usable.
Strategy, not just analysis
We start from the decision you are trying to make, not the method, and give you a clear recommendation.
We build the tools, not just the reports
In-house engineers turn the analysis into interactive dashboards, live models and decision tools your team can actually use, not static reports.
End to end, or just the part your team is missing
Run a full evidence programme with us, or bring us in for the single discipline your team is missing.
Across the lifecycle
Evidence is not a one-off. It has to keep up as things change.
The questions change as a product moves from planning to launch to clinical practice. Your evidence plan has to move with them.
Map and plan
Read the landscape, decide what each decision-maker will need, and design the evidence and the strategy to get there, before anything is locked in.
- Disease landscape and stakeholder mapping
- Evidence gap analysis against target HTA bodies
- Early value narrative and communication plan
- A roadmap tied to the launch sequence
Clear the bar, build support
Build the submission that survives review, and the narrative and engagement that move the people reviewing it.
- Value dossiers and HTA-grade evidence
- The value story and objection handling
- Advisory boards, publications and launch communications
- Payer, HTA and stakeholder engagement
Defend and expand
Keep the argument current as real-world use accumulates, to protect access and support expansion into new settings.
- Real-world outcomes in routine practice
- Evidence for reassessment and new indications
- Publications and ongoing stakeholder communication
- Stakeholder engagement as you enter new markets
Let's talk
Got a complex problem that needs a clear message?
Tell us the decision you are trying to influence. We will tell you what it would take to build the argument, and whether the data supports it.